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Edited by Laszlo NagyAbstract Overexpression of forkhead transcription factor
FOXC2 in white adipose tissue (WAT) leads to a lean phenotype
resistant to diet-induced obesity. This is due, in part, to enhanced
catecholamine-induced cAMP-PKA signaling in FOXC2 trans-
genic mice. Here we show that rolipram treatment of adipocytes
from FOXC2 transgenic mice did not increase isoproterenol-in-
duced cAMP accumulation to the same extent as in wild type
cells. Accordingly, phosphodiesterase-4 (PDE4) activity was re-
duced by 75% and PDE4A5 protein expression reduced by 30–
50% in FOXC2 transgenic WAT compared to wild type. Thus,
reduced PDE4 activity in adipocytes from FOXC2 transgenic
mice contributes to ampliﬁed b-AR induced cAMP responses
observed in these cells.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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We have previously shown that the forkhead transcription
factor FOXC2, when overexpressed in white adipose tissue
of mice, has a pleiotropic eﬀect on gene expression, showing in-
creased expression of genes involved in insulin signaling, glu-
cose uptake and lipolysis [1]. Among the genes regulated
were the b1,2,3-adrenergic receptors and the RIa regulatory
subunit of PKA [1,2], leading to increased sensitivity of the
badrenergic-cAMP-PKA signaling pathway. Accordingly, we
showed that catecholamine-induced cAMP accumulation is
ampliﬁed in adipocytes from FOXC2 transgenic mice com-
pared to adipocytes from wild type mice. These experiments
were performed in the presence of the non-selective phospho-Abbreviations: WAT, white adipose tissue; PDE, phosphodiesterase;
cAMP, cyclic adenosine-3 0,50-monophosphate; IBMX, isobutylmeth-
ylxanthine; b-AR, beta-adrenergic receptor; ADA, adenosine deami-
nase; CHA, cyclohexyladenosine
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doi:10.1016/j.febslet.2006.06.058diesterase (PDE) inhibitor IBMX to minimize hydrolysis of
cAMP by PDEs. Thus, the strongly enhanced and sustained
cAMP response previously observed in FOXC2 transgenic
adipocytes is most likely a result of the increased expression
of b-AR receptors, since this would lead to a more profound
activation of b-AR associated adenylyl cyclases (ACs) and,
thus, increased generation of cAMP from ATP. However,
reduced expression of cAMP-speciﬁc PDEs could also contrib-
ute to increased levels and duration of catecholamine-induced
cAMP accumulation in FOXC2 transgenic WAT. The PDE
enzymes belong to eleven related gene families (PDEs 1–11)
[3]. Of these the PDE3 and PDE4 families provide the major
route for degrading cAMP in cells such as adipocytes. In
adipocytes, phosphorylation and activation of PDE3B is the
major mechanism whereby insulin antagonizes catechol-
amine-induced lipolysis [4].
Four genes (4A/4B/4C/4D) encode the PDE4 enzyme family
[5]. Each of these generate a number of isoforms that are char-
acterized by unique N-terminal regions [5]. There is a strong
body of evidence showing that PDE3 and PDE4 underpin
compartmentalized cAMP signaling in cells by controlling spa-
tially distinct pools of cAMP [6]. This is achieved by diﬀerences
in intracellular targeting of these forms. The contribution of
PDE3 and PDE4 to cAMP hydrolysis and cAMP signaling
in cells can simply be gauged using appropriate selective inhib-
itors [7]. Thus, cilostamide selectivity inhibits PDE3 activity,
whilst rolipram is selective for PDE4.
Interestingly, Nakamura et al. [8] have shown that PDE4 has
anti-lipolytic capacity in fed rats, but not in starved rats, sug-
gesting that PDE4 expression and/or activity in mature adipo-
cytes is regulated according to food intake. Furthermore, in a
recent study by Snyder et al. [9] PDE4 inhibition with rolipram
had only moderate eﬀect on lipolysis in murine 3T3-L1 cells and
rat adipocytes, but simultaneous exposure to cilostamide and
rolipram had synergistic eﬀect on lipolysis in these cells, sup-
porting a role for PDE4 in suppression of lipolysis. The present
study was performed in order to elucidate any possible role for
either PDE3 or PDE4 in underpinning the phenotypic changes
seen in catecholamine-stimulated cAMP accumulation in adi-
pocytes fromFOXC2 transgenic mice. In doing this we ﬁnd that
PDE4A5 expression and basal PDE4 activity, but not PDE3
activity, are reduced in FOXC2 transgenic adipocytes, thereby
contributing to ampliﬁed b-AR-induced cAMP responses
observed in adipocytes from these transgenic animals.blished by Elsevier B.V. All rights reserved.
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2.1. Materials
The following chemicals were from Sigma: adenosine (A-9251),
adenosine deaminase (A-5168) CHA (C-9901), BSA (A-4503), fatty
acid free BSA (A-6003), IBMX (I-5879), and isoproterenol (I-2760).
Rolipram (557330) and cilostamide (231085) were from Calbiochem
and Collagenase A (103586) was from Roche. Mice-wild type and
FOXC2 transgenic (1) C57BL/6J mice were fed a standard chow with
4% (w/w) fat content.
2.2. Adipocyte preparation
Adipocytes were isolated from intraabdominal fat pads according to
the method of Rodbell [10]. All processing of cells were performed in
Krebs–Ringer solution buﬀered with 25 mMHepes at pH 7.5, contain-
ing 2.5 mM CaCl2 (KRH medium), 500 nM adenosine and 2 mM
glucose according to Honnor et al. [11].
2.3. cAMP assay
Adipocytes isolated from wild type and FOXC2 transgenic mice
(2 · 107 cells/ml) were incubated in KRH medium containing 4% fatty
acid free BSA, 1 U/ml adenosine deaminase and 100 nM CHA, in the
presence or absence of 1 lM isoproterenol, IBMX (100 lM), rolipram
(10 lM), cilostamide (1 lM) under constant agitation at 37 C. Aden-
osine deaminase was added in order to remove exogenous adenosine
and since this stimulates cAMP production, PKA activity and lipoly-
sis, CHA, a speciﬁc A1 receptor agonist was added to obtain cells at
basal conditions [12]. Equal amounts of cells (50 ll; 106 cells) were
withdrawn at diﬀerent time points, mixed with stop buﬀer containing
100 lM IBMX, and ﬂash-frozen. Intracellular cAMP levels were deter-
mined by radioimmunoassay (cAMP kit from NEN, Boston, MA,
Catalogue No. SMP004) according to the manufacturers instructions.
2.4. Immunoblotting
Intra-abdominal adipose tissues from wild type and FOXC2 trans-
genic mice were treated by a polytron tissue homogenizer (3 · 15 s)
and sonicated on ice in a buﬀer containing 10 mM potassium phos-
phate (pH 6.8), 150 mM sodium chloride, 5 mM MgCl2, 10 mM
CHAPS, Complete protease inhibitor mix (Roche), 2 mM sodium
orthovanadate, 1 mM phenylmethylsulfonyl ﬂuoride, and 50 mM so-
dium ﬂuoride (CHAPS/PE buﬀer), and centrifuged 15000 · g. Twenty
micrograms of total protein were separated by electrophoresis, and
subsequently transferred to polyvinylidene diﬂuoride membranes (Mil-
lipore, Bedford, MA) by semi-dry blotting. The membranes were blot-
ted with primary antibodies over night at 4 C in blocking solution.
Here, as previously described, we used speciﬁc polyclonal antibodies
to detect rodent PDE4A (AC55) [13] and PDEA5 [14]. Polyclonal
antibodies were also used to detect PDE3B [15], b-arrestin-1 (RDI)
and b-arrestin-2 (Santa Cruz Biotech).
2.5. PDE activity assay
Wild type and FOXC2 transgenic intra-abdominal adipose tissue
lysates were prepared in CHAPS/PE buﬀer as described above and
assayed, in duplicate, for total PDE activity as described before using
1 lM cAMP as substrate [16]. PDE3 activity was expressed as the
diﬀerence between activity with and without cilostamide, and PDE4
activity was expressed as the diﬀerence between activity with and with-
out rolipram. Protein concentrations were quantiﬁed and activities
were normalized for protein content.3. Results
3.1. Inhibition of PDE4 is essential for obtaining rapid
catecholamine-induced cAMP formation in adipocytes
In the absence of PDE inhibitors, challenge of adipocytes
with isoproterenol resulted in relatively small increases in
intracellular cAMP in both wild type and FOXC2 transgenic
cells, although 2 min after isoproterenol challenge a moderate
cAMP response was observed in the FOXC2 transgenic cells(Fig. 1A). However, in marked contrast to this, challenge with
isoproterenol in combination with IBMX, a non-selective
inhibitor that is able to inhibit all cAMP hydrolyzing PDEs ex-
cept PDE8 [17], led to a rapid and sustained (10 min) cAMP
response in FOXC2 transgenic cells (Fig. 1B). In wild type
cells, a similarly rapid increase in cAMP was noted, although
both the baseline cAMP level and amplitude of the response
were lower than in FOXC2 transgenic cells and the cAMP lev-
els returned to baseline after 10 min following stimulation
(Fig. 1B).
Treatment of cells with the PDE4 selective inhibitor, roli-
pram rescued the acute isoproterenol-induced cAMP response
in wild type cells, as also seen in the presence of IBMX, and
slightly enhanced the acute cAMP response in FOXC2 trans-
genic adipocytes (Fig. 1C). The cAMP level in rolipram-
treated wild type adipocytes was similar to that of FOXC2
transgenic cells stimulated with ispoproterenol in the absence
of PDE inhibitors (2.8 versus 2.9 pmol cAMP/106 cells), when
comparing isoproterenol-induced cAMP accumulation after
2 min of stimulation (Fig. 1C, wild type versus Fig. 1A,
FOXC2 transgene). Furthermore, rolipram treatment in-
creased isoproterenol-induced cAMP accumulation more in
wild type than in FOXC2 cells (0.9 versus 0.5 pmol cAMP/
106 cells). Treatment of wild type cells with the PDE3 inhibi-
tor, cilostamide enhanced basal and isoproterenol-stimulated
cAMP levels, but had no eﬀect in FOXC2 transgenic adipo-
cytes (Fig. 1D).
3.2. PDE4 activity is reduced in WAT from FOXC2 transgenic
mice
Based on the apparent diﬀerences in PDE-sensitive cAMP
accumulation between wild type and FOXC2 transgenic adipo-
cytes, we set out to investigate whether there were diﬀerences in
PDE activities between wild type and FOXC2 transgenic WAT
by performing PDE assays on WAT lysates. Interestingly, an
approximately 30% reduction in total cAMP-sepciﬁc PDE
activity compared to wild type (Fig. 2A) was observed. Basal
PDE4 activity in WAT from FOXC2 transgenic mice was re-
duced by approximately 75% as compared to wild type mice
(Fig. 2B). No diﬀerences in PDE3 activity was observed, whose
levels remained similar in FOXC2 transgenic and wild-type
WAT (Fig. 2C).
3.3. Reduced PDE4A expression in adipocytes from FOXC2
transgenic mice
Prompted by the reduced PDE4 activity in FOXC2 trans-
genic WAT, we investigated whether PDE4 expression was re-
duced in FOXC2 transgenic WAT. Immunoblotting using a
pan-PDE4 antibody (K116) [13] showed that an immunoreac-
tive band migrating at approximately 110–120 kDa was down-
regulated in FOXC2 transgenic WAT (data not shown). Based
on the size, we speculated that this could be a long PDE4A iso-
form; PDE4A5, A10 or A11. Immunoblotting with a PDE4A
speciﬁc antibody (Ac55), revealed that expression of a PDE4A
isoform migrating at approximately 110 kDa was reduced by
some 50% in FOXC2 transgenic WAT relative to wild type
(Fig. 3A and B). We were unable to detect expression of
PDE4A11 and detected only low levels of expression of
PDE4A10 with no diﬀerence in expression between wild type
and transgenic WAT (data not shown). Using a PDE4A5 spe-
ciﬁc antibody, we detected 30% lower expression level of this
isoform in FOXC2 transgenic WAT relative to wild type
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Fig. 1. Acute isoproterenol-induced cAMP accumulation in FOXC2 transgenic adipocytes is maintained in the absence of PDE inhibitors.
Adipocytes isolated from wild type and FOXC2 transgenic intraabdominal fat pads were preincubated for 15 min with ADA and CHA in the
absence (A) or presence of PDE inhibitors IBMX (B), cilostamide (C) and rolipram (D) (time 0) followed by stimulation with isoproterenol. Cells
were harvested 0-2-5 and 10 min after stimulation and assayed for intracellular cAMP. Statistical analysis was performed using Student’s unpaired
t-test. * denote signiﬁcant diﬀerences where P 6 0.05. Data represents mean ± S.E.M. from three individual experiments performed in duplicate.
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Fig. 2. PDE4 activity is reduced in FOXC2 transgenic mice. Wild type and FOXC2 transgenic WAT lysates were assayed for total PDE activity (A),
PDE4 activity (B) and PDE3 activity (C). The data represents the mean ± S.E.M. from three (B and C) and six (A) individual experiments performed
in duplicate. Statistical analysis was performed using Student’s unpaired t-test. ** denote signiﬁcant diﬀerences where P 6 0.01.
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levels of PDE4B, 4C, 4D (not shown) or PDE3B between wild
type and FOXC2 transgenic WAT (Fig. 3A).
Since various PDE4 isoforms are able to be recruited to
ligand-activated b-adrenergic receptors via association with
b-arrestins [18], we also examined b-arrestin levels. However,
we did not detect any diﬀerence in expression levels of either
b-arrestin-1 (Fig. 3A) or b-arrestin-2 (not shown) between wild
type and FOXC2 transgenic WAT.4. Discussion
Mice over-expressing FOXC2 in WAT have increased cate-
cholamine-induced cAMP accumulation and lowered thresh-
old for PKA activation by cAMP [1]. This increased
signaling through the b-AR-cAMP-PKA pathway can, at least
in part, explain the lean phenotype of FOXC2 transgenic
WAT. In this study, we set out to elucidate the eﬀect of
PDE inhibitors on b-AR-induced cAMP levels in wild type
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Fig. 3. PDE4A5 protein expression levels are reduced in FOXC2
transgenic WAT. (A) Wild type and FOXC2 transgenic WAT lysates
were prepared and examined by immunoblotting using antibodies
against PDE4A, PDE4A5, PDE3B and b-arrestin-1. Mobilities of the
Precision Plus protein standard (Bio-Rad) is shown. (B) The PDE4A
and PDE4A5 immunoreactive bands in A were quantiﬁed using the
Quantity One software (Version 4.5; Bio-Rad). Bars represent inten-
sities of PDE4A and PDE4A5 in FOXC2 transgenic WAT relative to
that in wild type (set to 100%). Statistical analysis was performed using
Student’s unpaired t-test. * denote P 6 0.05.
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with isoproterenol together with the non-selective PDE inhib-
itor, IBMX resulted in higher cAMP levels in FOXC2 trans-
genic adipocytes compared to wild type cells.
Neither rolipram nor cilostamide increased isoproterenol-
induced cAMP accumulation to the same degree as the non-
selective PDE inhibitor, IBMX in wild type and FOXC2
transgenic cells suggesting that simultaneous inhibition of
PDE3 and PDE4 is necessary for optimal cAMP accumula-
tion. As PDE4 and PDE3 represent compartmentalized PDE
activities, cAMP elevations after inhibition of each isoform
alone will contribute to local elevations in cAMP that may
be diluted when measuring whole cell cAMP levels. This may
be the reason why the eﬀect of rolipram is less pronounced
than that of IBMX. A recent paper by Snyder et al. [9] shows
that cilostamide and rolipram acts synergistically and in a sim-
ilar way as IBMX on the rate of lipolysis in rat and mouse adi-
pocytes, suggesting that inhibition of both PDE3 and PDE4 is
required for maximal lipolysis in adipocytes. Due to the low
triglyceride content of FOXC2 transgenic WAT, glycerol re-
lease after isoproterenol treatment is extremely low (1.5-fold)
by 1 lM isoproterenol in the absence of PDE inhibitors for
2 h at 37 C as compared to wild type adipocytes (10-fold)
(data not shown). This conﬁrms that only small increases in
cAMP levels results in profound eﬀects on lipolysis in wild type
adipocytes. PDE4 inhibition with rolipram did not amplify iso-
proterenol-induced cAMP levels in FOXC2 transgenic cells to
the same extent as in wild-type cells, suggesting reduced PDE4
activity in FOXC2 transgenic cells. PDE3 inhibition did not
eﬀect isoproterenol-induced cAMP accumulation in FOXC2transgenic adipocytes with only a small increase in wild-type
cells. Our ﬁnding that rolipram was able to increase isoprote-
renol-stimulated cAMP accumulation to a greater extent than
cilostamide in wild-type cells is in agreement with previous
observations [19]. Our PDE activity analyses revealed a 75%
reduction in PDE4 activity in FOXC2 transgenic WAT com-
pared to wild type WAT with no diﬀerence in PDE3 activity.
Total cAMP-speciﬁc PDE activity was reduced by 30% in
FOXC2 transgenic cells indicating that PDE4 is the main reg-
ulated PDE in FOXC2 transgenic adipocytes.
PDE4 isoforms, including PDE4A5, can be recruited to the
plasma membrane via association with b-arrestin, leading to
desensitization of ligand-activated b-adrenergic receptors and
quenching of PKA activity [18]. Loss of acute (2 min) b-adren-
ergic cAMP activation in isoproterenol-treated wild type cells,
which is simply rescued by PDE inhibition through treatment
with either IBMX or rolipram, but not cilostamide, indicates
that PDE4, at least in part, controls inhibition of acute
b2-AR-induced cAMP formation in adipocytes.
These data together with our observation that PDE4A5 is
expressed in b2-AR containing lipid rafts/caveolae of 3T3-L1
adipocytes (data not shown), supports a role for PDE4 con-
trolling membrane/receptor associated PKA activity mediating
attenuation of basal and catecholamine-induced cAMP accu-
mulation in adipocytes. Reduced PDE4A5 expression in
FOXC2 transgenic adipocytes would, consequently, contribute
to the ampliﬁed cAMP levels observed in these cells.
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